Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

All articles by Andrea S. Blevins Primeau, PhD, MBA

Man reading pill bottle

Genitourinary Cancers Symposium

Niraparib Maintenance Failed to Improve Outcomes in Advanced Urothelial Carcinoma

By

Andrea S. Blevins Primeau, PhD, MBA

March 10, 2022

The median progression-free survival was similar between the treatment arms.

Chemotherapy

Genitourinary Cancers Symposium

Neoadjuvant Chemotherapy Deemed New Standard Care in Urothelial Carcinoma

By

Andrea S. Blevins Primeau, PhD, MBA

March 8, 2022

The study’s primary endpoint was met, and neoadjuvant chemotherapy was considered well tolerated.

Researcher in lab

Prostate Cancer

AI Tool More Accurately Predicts Long-Term Outcomes in Prostate Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

March 7, 2022

An AI tool outperformed NCCN guidelines for predicting biochemical failure, distant metastasis, prostate cancer-specific survival, and overall survival.

The novel drug appeared effective in healthy, previously untreated patients, but cost, side effects, and other issues may stand in the way of its widespread use.

Genitourinary Cancers Symposium

Prostate Cancer Screening and Treatment Patterns Differ Across Countries

By

Andrea S. Blevins Primeau, PhD, MBA

March 1, 2022

Compared with German and US patients, UK patients were less likely to be diagnosed with prostate cancer via routine screening.

Kidney cancer

Atezolizumab Plus Bevacizumab Does Not Improve OS in Renal Cell Carcinoma

By

Andrea S. Blevins Primeau, PhD, MBA

January 10, 2022

The overall survival results were similar between the treatment arms for the overall cohort and for patients with PD-L1+ disease.

PSA blood test

Prostate Cancer

PSA Screening Recommendation Tied to Decrease in Prostate Cancer-Specific Survival

By

Andrea S. Blevins Primeau, PhD, MBA

October 19, 2021

The 3-year prostate cancer-specific survival decreased significantly for insured patients.

A patient with cancer receives palliative care.

Sex Inequalities Persist in Cancer Clinical Trials

By

Andrea S. Blevins Primeau, PhD, MBA

October 7, 2021

Men nearly always outnumbered women, regardless of trial phase, cancer type, time period, or cancer incidence in the female population.

Masked patient in hospital bed.

Cancer Patients With COVID-19 Less Likely to Receive Critical Care Despite Higher Risk of Death

By

Andrea S. Blevins Primeau, PhD, MBA

October 6, 2021

Cancer patients were less likely to receive critical care, whether they were on active anticancer treatment or not.

Doctor and patient wearing masks.

Long-Term COVID-19 Symptoms Linked to Treatment, Survival of Cancer Patients

By

Andrea S. Blevins Primeau, PhD, MBA

September 30, 2021

Long-term symptoms included shortness of breath, chronic fatigue, and neurocognitive dysfunction.

Multiple patients having chemotherapy in a room

dd-MVAC Regimen ‘Should Be Gold Standard’ for Muscle-Invasive Bladder Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

September 17, 2021

Dose-dense methotrexate plus vinblastine, doxorubicin, and cisplatin improved time to progression.

Next post in Bladder Cancer

Blood-Based Test May Establish a ‘New Paradigm’ for Cancer Screening